Aktis Oncology, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Aktis Oncology (clinical-stage radiopharmaceutical company, $557.6M total assets) reported Q2 2026 results: cash/equivalents/marketable securities increased to $517.3M (from $226.8M at Dec 31, 2025) following January 2026 IPO; collaboration revenue $3.4M (vs. $1.6M prior year); R&D expenses $25.3M (vs. $18.6M); net loss $24.1M (vs. $18.1M prior year). Runway extends to 2029. Key progress: presented first-in-human AKY-2519 imaging/dosimetry data at ASCO (May 2026); ongoing Phase 1b trials for AKY-1189 (Nectin-4) and AKY-2519 (B7-H3); Phase 1b BActinium-2 trial cleared for initiation in H2 2026; GMP facility operationalization on track for H2 2026.
Why this rating
IPO funding ($290M net cash increase) substantially de-risks near-term operations (3+ years runway); clinical progress evident but early stage. Meaningful for company trajectory but routine for biotech at this stage.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.